Combinatorial therapy with sulindac, a non‐steroidal anti‐inflammatory drug (Chandra et al. 2017; Yin et al. 2016) and adenovirus expressing IL‐24 was assessed in in vitro and in vivo NSCLC models and demonstrated enhanced growth inhibition compared with monotherapy. The gene discussed is IL24; the disease is non-small cell lung carcinoma.